Project Grant R01AG093848
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $653K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded the University of Pittsburgh $664,619 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop multiscale computational and experimental models of neurometabolic coupling across age-related cognitive decline and late-onset Alzheimer's disease. The research integrates in vivo two-photon microscopy, multispectral wide-field imaging, and magnetic resonance imaging to characterize the relationship between neuronal activity and metabolic...
- The National Institute on Aging awarded $128,250 to Weill Medical College of Cornell University on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate modifiers of human microglia-neuron interplay in tau propagation in vivo. The research employs a human neuron-microglia chimera platform that integrates human neurons, astrocytes, and microglia into the mouse brain to model Alzheimer's disease and frontotemporal dementia pathology. Aim 1 investigates molecular...
- The National Institute on Aging awarded University of Massachusetts Medical School $445,130 on January 1, 2026, under the Aging Research program (CFDA 93.866) to support research elucidating the mechanisms by which MS4A genes regulate neurodegeneration in Alzheimer's disease and related disorders. The research investigates how genetic deletion and polymorphisms of MS4A family genes—particularly MS4A6C, MS4A4A, MS4A4E, and MS4A6E—affect disease progression across multiple neurodegenerative...
- The National Institute on Aging awarded Georgetown University $156,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mitigation strategies for network dysfunction in Alzheimer's disease pathology. The project tests whether mild hyperpolarization can stabilize hippocampal network activity despite amyloid-beta-related impairment of excitatory amino acid transporters. The research quantifies sharp wave-ripples in ex vivo hippocampal slices from 5XFAD transgenic...
- The National Institute on Aging awarded the University of Massachusetts Medical School $419,946 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into RNA interference-mediated modulation of apolipoprotein E, innate immune response, and tau pathology as a disease-modifying treatment for Alzheimer's disease. The funded research develops and tests small interfering RNA scaffolds that simultaneously target multiple genes implicated in Alzheimer's disease progression....
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Northwestern University $457,112 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of toxic short RNAs (sRNAs) and the DISE (Death Induced by Survival Elimination) mechanism in neurodegenerative diseases, particularly Alzheimer's disease and Huntington's disease. The research examines how G-rich sRNAs target survival genes through miRNA-like pathways and explores why normal tissues remain protected from this cell...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...